A Prospective Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer

Trial Profile

A Prospective Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Apatinib (Primary) ; Gimeracil/oteracil/tegafur; Paclitaxel
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Acronyms Ahead-G325
  • Most Recent Events

    • 06 Jun 2017 Results assessing the efficacy and safety of apatinib plus chemotherapy in vivo (n=4) and in vitro, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 21 Jan 2017 Results (n=33) evaluating the efficacy and safety of S1/paclitaxel chemotherapy plus apatinib in patients with unresectable gastric cancer, presented at the 2017 Gastrointestinal Cancers Symposium.
    • 24 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top